Cancer Research and Treatment Fund, Inc.

Financial Statements

December 31, 2019 and 2018

Sassetti

CERTIFIED PUBLIC ACCOUNTANTS

CANCER RESEARCH AND TREATMENT FUND, INC.

FINANCIAL STATEMENTS

DECEMBER 31, 2019 AND 2018

TABLE OF CONTENTS

Board of Directors
Cancer Research and Treatment Fund, Inc.
New York, New York

INDEPENDENT AUDITORS' REPORT

We have audited the accompanying financial statements of **Cancer Research and Treatment Fund, Inc.** (a nonprofit organization) which comprise the statements of financial position as of December 31, 2019 and 2018, and the related statements of activities, functional expenses, and cash flows for the years then ended, and the related notes to the financial statements.

Management's Responsibility for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

6611 W. North Avenue ▪ Oak Park, IL 60302 ▪ P 708.386.1433 ▪ F 708.386.0139 ▪ www.sassetti.com

Sassetti
CERTIFIED PUBLIC ACCOUNTANTS

Opinion

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of **Cancer Research and Treatment Fund, Inc.** as of December 31, 2019 and 2018, and the changes in its net assets and its cash flows for the years then ended, in accordance with accounting principles generally accepted in the United States of America.

Sassetti LLC

Oak Park, Illinois
July 23, 2020

CANCER RESEARCH AND TREATMENT FUND, INC.

STATEMENTS OF FINANCIAL POSITION

DECEMBER 31, 2019 AND 2018

	2019	2018
ASSETS		
CURRENT ASSETS		
Cash and cash equivalents	$ 957,889	$ 1,119,135
Investments	11,995,153	10,102,091
Pledges receivable	-	5,000
Prepaid expenses and other assets	11,232	11,291
Total Current Assets	12,964,274	11,237,517
Property and equipment, net	7,378	-
Restricted cash	-	13,535
TOTAL ASSETS	$ 12,971,652	$ 11,251,052
LIABILITIES AND NET ASSETS		
CURRENT LIABILITIES		
Grants payable	$ 557,000	$ 417,000
Accounts payable	373	828
Accrued expenses	89,050	28,100
Total Current Liabilities	646,423	445,928
NET ASSETS		
Without donor restrictions	12,325,229	10,791,677
With donor restrictions	-	13,447
Total Net Assets	12,325,229	10,805,124
TOTAL LIABILITIES AND NET ASSETS	$ 12,971,652	$ 11,251,052

The accompanying notes are an integral part
of the financial statements.

CANCER RESEARCH AND TREATMENT FUND, INC.

STATEMENTS OF ACTIVITIES

YEARS ENDED DECEMBER 31, 2019 AND 2018

	2019			2018		
	Without Donor Restrictions	With Donor Restrictions	Total	Without Donor Restrictions	With Donor Restrictions	Total
INCOME AND OTHER SUPPORT						
Contributions	$ 345,351	$ -	$ 345,351	$ 475,846	$ -	$ 475,846
Fundraising income	352,005	-	352,005	376,123	-	376,123
Symposium revenue	77,275	-	77,275	-	-	-
Investment income, net of fees of $81,064 and $88,914, respectively	500,063	2	500,065	782,756	1	782,757
Unrealized and realized gains (losses)	1,543,269	-	1,543,269	(1,259,367)	-	(1,259,367)
Net assets released from restrictions	13,449	(13,449)	-	-	-	-
Total Income and Other Support	2,831,412	(13,447)	2,817,965	375,358	1	375,359
EXPENSES						
Program	1,008,047	-	1,008,047	956,008	-	956,008
Fundraising	232,311	-	232,311	255,601	-	255,601
General and administrative	57,502	-	57,502	55,922	-	55,922
Total Expenses	1,297,860	-	1,297,860	1,267,531	-	1,267,531
CHANGE IN NET ASSETS	1,533,552	(13,447)	1,520,105	(892,173)	1	(892,172)
NET ASSETS						
Beginning of year	10,791,677	13,447	10,805,124	11,683,850	13,446	11,697,296
End of of year	$ 12,325,229	$ -	$ 12,325,229	$ 10,791,677	$ 13,447	$ 10,805,124

The accompanying notes are an integral part of the financial statements.

CANCER RESEARCH AND TREATMENT FUND, INC.

STATEMENT OF FUNCTIONAL EXPENSES

YEAR ENDED DECEMBER 31, 2019

	Program Services	Fundraising	Management and General	Total
Payroll and related expenses				
Salaries	$ 41,506	$ 53,365	$ 23,718	$ 118,589
Payroll taxes and related costs	3,551	4,567	2,030	10,148
	45,057	57,932	25,748	128,737
Grants				
Grants for the Silver MPN Center	849,000	-	-	849,000
Grants for research support	34,318	-	-	34,318
	883,318	-	-	883,318
Other				
Direct fundraising expenses	-	102,930	-	102,930
MPN Patient Symposium	24,098	-	-	24,098
Rent	14,292	18,374	8,166	40,832
Newsletter and public relations	16,817	21,621	9,609	48,047
Office and other miscellaneous	9,416	12,107	5,381	26,904
Meetings	3,662	4,707	2,092	10,461
Professional fees	10,610	13,641	6,063	30,314
Telephone	454	584	259	1,297
Depreciation	323	415	184	922
	79,672	174,379	31,754	285,805
Total Expenses	$ 1,008,047	$ 232,311	$ 57,502	$ 1,297,860

The accompanying notes are an integral part of the financial statements.

CANCER RESEARCH AND TREATMENT FUND, INC.

STATEMENT OF FUNCTIONAL EXPENSES

YEAR ENDED DECEMBER 31, 2018

	Program Services	Fundraising	Management and General	Total
Payroll and related expenses				
Salaries	$ 38,963	$ 50,094	$ 22,264	$ 111,320
Payroll taxes and related costs	3,429	4,408	1,959	9,796
	42,392	54,502	24,223	121,116
Grants				
Grants for the Silver MPN Center	834,000	-	-	834,000
Grants for research support	24,143	-	-	24,143
	858,143	-	-	858,143
Other				
Direct fundraising expenses	-	129,776	-	129,776
Rent	14,204	18,261	8,116	40,580
Newsletter and public relations	16,338	21,006	9,336	46,681
Office and other miscellaneous	10,055	12,928	5,746	28,728
Meetings	2,786	3,583	1,592	7,962
Professional fees	10,756	13,829	6,146	30,732
Telephone	1,334	1,716	763	3,813
	55,473	201,099	31,699	288,272
Total Expenses	$ 956,008	$ 255,601	$ 55,922	$ 1,267,531

The accompanying notes are an integral part
of the financial statements.

CANCER RESEARCH AND TREATMENT FUND, INC.

STATEMENTS OF CASH FLOWS

YEARS ENDED DECEMBER 31, 2019 AND 2018

	2019	2018
CASH FLOWS FROM OPERATING ACTIVITIES		
Change in net assets	$ 1,520,105	$ (892,172)
Adjustments to reconcile change in net assets to net cash provided by operating activities -		
Unrealized and realized (gains) losses on investments	(1,543,269)	1,259,367
Donated investments	(134,092)	(8,552)
Depreciation	922	-
(Increase) decrease in operating assets:		
Pledges receivable	5,000	(5,000)
Prepaid expenses and other assets	59	141
Increase (decrease) in operating liabilities:		
Grants payable	140,000	417,000
Accounts payable	(455)	(1,956)
Accrued expenses	60,950	(9,680)
Net Cash Provided by Operating Activities	49,220	759,148
CASH FLOWS FROM INVESTING ACTIVITIES		
Purchases of property and equipment	(8,300)	-
Proceeds from sales and maturity of investments	3,293,913	3,602,541
Purchases of investments	(3,509,614)	(3,751,855)
Net Cash Used in Investing Activities	(224,001)	(149,314)
NET (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS	(174,781)	609,834
CASH AND CASH EQUIVALENTS:		
Beginning of year	1,132,670	522,836
End of year	$ 957,889	$ 1,132,670
SUMMARY OF CASH AND CASH EQUIVALENTS		
Unrestricted	$ 957,889	$ 1,119,135
Restricted	-	15,535
	$ 957,889	$ 1,134,670

The accompanying notes are an integral part of the financial statements.

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations – Cancer Research and Treatment Fund, Inc. ("the Organization") is a not-for-profit organization founded to fund cancer research and treatment, emphasizing myeloproliferative neoplasms and other common blood and solid tumor cancers. Funding is granted to individuals for research in connection with cancer related disorders. Revenue and support for the Organization are primarily from the general public.

Basis of Accounting - Under generally accepted accounting principles, the Organization is required to report information regarding its financial position and activities according to two classes of net assets: net assets without donor restrictions and net assets with donor restrictions. The net assets of the Organization are reported in the two self-balancing groups as follows:

- Net Assets without Donor Restrictions: Net assets without donor restrictions are for use at the discretion of the Board of Directors (the Board) and/or management for general operating purposes. From time to time, the Board designates a portion of these net assets for specific purposes which makes them unavailable for use at management's discretion.

- Net Assets with Donor Restrictions: Net assets with donor restrictions consist of assets whose use is limited by donor-imposed time and/or purpose restrictions. The Organization reports gifts of cash and other assets as revenue with donor restrictions if they are received with donor stipulations that limit the use of the donated assets. When a donor restriction expires, that is, when a stipulated time restriction ends or purpose restriction is accomplished, the net assets are reclassified as net assets without donor restriction and reported in the statements of activities as net assets released from restrictions. Some net assets with donor restrictions include a stipulation that assets provided be maintained permanently (perpetual in nature) while permitting the Organization to expend the income generated by the assets in accordance with the provisions of additional donor imposed stipulations or a Board approved spending policy.

Cash Flow Information – For purposes of the Statements of Cash Flows, the Organization considers all unrestricted highly liquid investments with an initial maturity of three months or less to be cash equivalents. No cash was paid for income taxes or interest during the years ended December 31, 2019 and 2018.

Revenue Recognition – Contributions received are recorded as without donor restrictions or with donor restrictions, depending on the existence or nature of any donor restrictions. All contributions are considered to be available for unrestricted use unless specifically restricted by the donor. Amounts received that are designated for future periods or restricted by the donor for specific purposes are reported as donor restricted support that increases the restricted net asset class. If a restriction is fulfilled in the same time period in which the contribution is received, the Organization reports the contribution as without donor restrictions.

Event revenue is recognized at a point in time when the particular event occurs.

Estimates – The accompanying financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP), which required management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Accordingly, actual results could differ from those estimates.

Investments – Equity, bond, and governmental securities are carried at fair value. The fair value of other investments has been estimated using the Net Asset Value ("NAV") as reported by the management of the respective other investment funds.

Interest and dividends are recorded when earned. Purchases and sales of securities are recorded on a trade-date basis. Interest income is recorded on the accrual basis and dividends are recorded on the ex-dividend date. Realized and unrealized gains and losses are included in the determination of income.

Property and Equipment – Property and equipment are stated at cost. Expenditures for major additions and improvements above $5,000 are capitalized, while minor repairs and maintenance are charged to expense as incurred. Depreciation is based on the estimated useful lives of depreciable assets and is provided using the straight-line method. When property is disposed, the asset and the accumulated depreciation are removed from the accounts. Any resulting gain or loss is reflected in operations in the period incurred.

Donated Services – Many individuals volunteer their time and perform a variety of tasks that assist the Organization with specific programs, campaign solicitations, and various committee assignments. Volunteer hours received by the Organization are not recognized in the financial statements because they did not meet the criteria for recognition under U.S. GAAP, which states that in order to record the value of services, the services must either (a) create or enhance non-financial assets, or (b) the service must require specialized skills.

Tax-Exempt Status – The Organization is a not-for-profit institution exempt from federal income taxes under Section 501(c)(3) of the U.S. Internal Revenue Code. Accordingly, no provisions for income taxes have been provided in the accompanying financial statements.

The Organization follows U.S. GAAP guidance on *Accounting for Uncertainty in Income Taxes*. This topic provides guidance on the recognition, measurement, classification and disclosures related to uncertain tax positions, along with any interest and penalties. The Organization continually evaluates the possible existence of uncertain tax positions. The federal and state tax returns of the Organization are subject to examination, generally for three years after filing.

Adopted Accounting Pronouncements – In May 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2014-09, Revenue from Contracts with Customers (Topic 606), requiring an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. The updated standard replaced most existing revenue recognition guidance in U.S. GAAP. Early adoption is permitted. The updated standard was adopted for the Organization's year ending December 31, 2019.

In January 2016, the FASB issued ASU 2016-01, Recognition and Measurement of Financial Assets and Financial Liabilities, and subsequently issued related ASU 2018-03, Technical Corrections and Improvements to Financial Instruments. These standards amend certain aspects of accounting and disclosure requirements for financial instruments, including the requirement that equity investments with readily determinable fair values are to be measured at fair value with any changes in fair value recognized in the statement of changes in net assets. The Organization adopted this standard for the year ending December 31, 2019.

There were no significant changes caused by adoption of these pronouncements.

2. CONCENTRATIONS

The Organization maintains cash balances in financial institutions. The balances are insured by the Federal Deposit Insurance Corporation. The Organization's bank balances may at times exceed insurable limits. The Organization has not experienced any losses in such accounts and as a result believes it is not exposed to any significant financial risk.

The Organization maintains an investment portfolio that contains non-traditional, not readily marketable investments. The underlying investments of such funds, whether invested in stock or other securities, are generally not currently traded in a public market and typically are subject to restrictions on resale. Values determined by managers or general managers of underlying securities may be based on ongoing operational due diligence and risk monitoring of underlying investment funds. At December 31, 2019 and 2018, the Organization's investment in these types of funds comprised 49% and 53% of total investments, respectively.

3. INVESTMENTS

Investments consist of the following at December 31, 2019:

	2019		
	Cost	Fair Value	Unrealized Gain (Loss)
Municipal bonds	$ 2,770	$ 2,750	$ (20)
Equity securities	4,670,725	6,080,369	1,409,644
Non-equity correlated	1,946,605	2,967,486	1,020,881
Hedged equities	1,267,893	2,732,048	1,464,155
Private credit equities	212,500	212,500	-
Total	$ 8,100,493	$ 11,995,153	$ 3,894,660

Investments consist of the following at December 31, 2018:

	2018		
	Cost	Fair Value	Unrealized Gain (Loss)
U.S. government securities	$ 249,532	$ 248,863	$ (669)
Municipal bonds	2,709	2,623	(86)
Equity securities	3,966,346	4,475,003	508,657
Non-equity correlated	2,096,605	2,924,863	828,258
Hedged equities	1,417,893	2,450,739	1,032,846
Total	$ 7,733,085	$ 10,102,091	$ 2,369,006

4. FAIR VALUE MEASUREMENTS

FASB ASC Topic 820, Fair Value Measurements and Disclosures, provides a framework for measuring fair value. That framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. Fair value focuses on the price that would be received to sell the asset or paid to transfer the liability regardless of whether an observable liquid market price existed (an exit price). An exit price valuation will include margins for risk even if they are not observable. As the Organization is released from risk, the margins for risk will also be released through net realized gains (losses) in net income (loss). The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). The three levels of the fair value hierarchy are described as follows:

Level 1 – Valuation is based upon quoted prices in active markets for identical assets.

Level 2 – Valuation based on inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or dissimilar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data fur substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity, and that are significant to the fair value of the assets or liabilities.

The asset or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques used need to maximize the use of observable inputs and minimize the use of unobservable inputs. There are no changes in the valuation of methodologies used at December 31, 2019 and 2018.

Fair values for marketable securities are determined by reference to quoted market prices and other relevant information generated by market transactions.

Fair values of assets measured on a recurring basis were as follows:

	Fair Value Measurements at December 31, 2019			
	Level 1	Level 2	Level 3	Total
Municipal bonds	$ 2,750	-	-	$ 2,750
Equity securities	6,080,369	-	-	6,080,369
	$ 6,083,119	$ -	$ -	6,083,119
Other investments:				
Non-equity correlated [(a)]				2,967,486
Hedged equities [(a)]				2,732,048
Private credit equities [(a)]				212,500
Total investments, at fair value				$ 11,995,153

	Fair Value Measurements at December 31, 2018			
	Level 1	Level 2	Level 3	Total
U.S. government securities	$ 248,863	$ -	$ -	$ 248,863
Municipal bonds	2,623	-	-	2,623
Equity securities	4,475,003	-	-	4,475,003
	$ 4,726,489	$ -	$ -	4,726,489
Other investments:				
Non-equity correlated [(a)]				2,924,863
Hedged equities [(a)]				2,450,739
Total investments, at fair value				$ 10,102,091

(a) In accordance with current accounting standards, certain investments that are measured at fair value using the NAV per share “Practical Expedient” have not been classified in the fair value hierarchy. The fair value amounts presented in these tables are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the statements of financial position.

Non-equity correlated, hedged equities, and private credit equities employ a variety of investment strategies with varying net/gross exposure levels. The fair values of the investment in this category are those reported by the fund administrator at December 31, 2019 and 2018. Liquidity terms vary by fund, with certain funds offering flexible terms. The investment strategies are summarized as follows:

- Credit Strategies employ an investment process focused on identifying corporate credit instruments that are either undervalued or overvalued to their fair value. Managers typically employ a fundamentally-oriented investment process to identify mispriced credit instruments.
- Distressed Debt Strategies employ an investment process focused on identifying corporate credit instruments trading at significant discounts to their fair value. Managers are typically actively involved with these companies, often through participation in creditors’ committees or other restructuring decisions.

- Event Driven Strategies relate to situations in which the underlying investment opportunity and risk is associated with an event. An Event Driven investment strategy finds investment opportunities in transactional events including but not limited to mergers, restructurings, financial distress, tender offers, shareholder buybacks, security issuance or other capital structure adjustments.
- Macro Investment Strategies take position in share, bond or currency markets in anticipation of global macroeconomic events in order to generate a risk-adjusted return. Macro fund managers use macroeconomic analysis based on global market events and trends to identify opportunities for investment that would profit from anticipated price movements.
- Market Neutral Strategies exhibit zero correlation with an unwanted source of risk.
- Long/Short Equity Strategies involve buying long equities that are expected to increase in value and selling short equities that are expected to decrease in value.
- Multi-Strategy Funds engagement in variety of investment strategies, including but not limited to long/short equity, market neutral, event driven and global macro.
- Private Credit Strategies generate attractive risk-adjustment net returns by investing in a portfolio of funds that engage in private credit and/or lending transactions, including funds that either make loans to middle-market business or invest in a diversified portfolio of commercial real estate-related debt and securities.

5. NET ASSETS WITHOUT DONOR RESTRICTIONS

Net assets without donor restrictions are available for use at the discretion of the Board of Directors (the Board) and/or management for general operating purposes. Board designated net assets represent amounts identified by the Board which have been invested for use at management's discretion. Income earned on such balances accrues and, with approval of the Board, may be used to support the Organization's activities.

The following summarizes activity for net assets with board designated restrictions during 2019 and 2018:

	2019	2018
Net assets with board designated restrictions, January 1:	$ 10,509,097	$ 11,310,706
Investment income, net of fees	500,063	782,758
Unrealized and realized gains (losses)	1,543,269	(1,259,367)
Less: transfers	(650,000)	(325,000)
Net assets with board designated restrictions, December 31:	$ 11,902,429	$ 10,509,097

The following summarizes ending balances of all net assets without donor restrictions at December 31, 2019 and 2018:

	2019	2018
Board designated	$ 11,902,429	$ 10,509,097
Undesignated net assets	422,800	282,580
Net assets without donor restrictions	$ 12,325,229	$ 10,791,677

6. NET ASSETS WITH DONOR RESTRICTIONS

Certain programs carried on by the Organization are funded by third party contributions and grants from pharmaceutical companies which are earmarked towards specific research programs presently being conducted, as well as programs to begin in the future. These funds are classified as restricted cash on the Statement of Financial Position, and its use is restricted to the designated program for which the revenue was received. The balance in this fund at December 31, 2019 and 2018 is $0 and $13,535, respectively, and represents donations for neurological research in brain and prostate cancer research.

7. PROPERTY AND EQUIPMENT

Major classifications of property and equipment, and their respective useful lives, are as follows at December 31:

	2019	2018	Estimated Useful Lives
Webpage	$ 50,300	$ 42,000	3 - 7 years
Leasehold improvements	19,201	19,201	39 years
Computer	16,573	16,573	5 years
Furniture	6,806	6,806	7 years
Equipment	2,351	2,351	5 - 7 years
	95,231	86,931	
Less: accumulated depreciation	(87,853)	(86,931)	
	$ 7,378	$ -	

Depreciation expense for the year ended December 31, 2019 was $922. The Organization did not have any depreciation expense for the year ended December 31, 2018.

7. RESTRICTED CASH

Certain programs carried on by the Organization are funded by third party contributions and grants from pharmaceutical companies which are earmarked towards specific research programs presently being conducted, as well as programs to begin in the future. The use of these funds is restricted to the designated programs for which the revenue was received. The balance in this fund at December 31, 2019 and 2018 is $0 and $13,535, respectively, and represents donations for neurological research in brain and prostate cancer research.

8. LEASE

The Organization leases its facilities in New York, New York from an independent party, which expires on January 31, 2022. Rent paid for this facility totaled $40,832 and $40,580 for the years ended December 31, 2019 and 2018.

Future minimum lease payments under operating leases are as follows for the year ended December 31:

2020	$	42,329
2021		43,213
2022		3,604
Total	$	89,146

9. COMMITMENTS AND CONTINGENCIES

The Organization made an initial pledge of $3,700,000 in 2011 to the Weill Cornell Medical College (the "College") for the purpose of creating the Richard T. Silver, M.D. Myeloproliferative Neoplasm Center (the "Silver MPN Center"). The pledge was subsequently and most recently modified in 2019, increasing the total pledge to $6,574,000. As of December 31, 2019 and 2018, the remaining unpaid pledge amounted to $1,357,000 and $1,651,000, respectively.

The pledged amounts remaining as of December 31, 2019 are to be paid as follows:

- A gift of $167,000 is classified as grants payable on the 2019 Statement of Financial Position for amounts approved by the Board but unpaid to support the Scientific Director of Silver MPN Center in their laboratory research.
- A gift of $50,000 is classified as grants payable on the 2019 Statements of Financial Position for amounts approved by the Board but unpaid to support a clinician.
- A gift of $340,000 is classified as grants payable on the 2019 Statements of Financial Position for amounts approved by the Board but unpaid to support clinical research at the Silver MPN Center.
- A gift of $700,000, payable in two annual installments, commencing upon the hiring of a Clinical Director of the Silver MPN Center.
- A gift of $100,000, payable in installments of $50,000 in July 2020 and December 2020 to support a new clinician.

The amounts and timing of these gifts are also subject to the terms and conditions stated in the pledge agreements.

The remaining gifts will be recorded as amounts are determined and approved annually by the Organization's Board.

10. MAJOR CONTRIBUTORS

For the year ended December 31, 2019, two gifts totaling $290,000 comprised approximately 84% of total contributions. These gifts have no restrictions on their use.

For the year ended December 31, 2018, four gifts totaling $405,000 comprised approximately 85% of total contributions. These gifts have no restrictions on their use.

11. LIQUIDITY AND AVAILABILITY OF RESOURCES

The Organization operates on a consistent annual cycle, with their primary expenditures related to the payment of pledge commitments, and various other budgeted administrative and fundraising expenses.

The Organization's financial assets available within one year of the statements of financial position date for general expenditures are as follows:

	December 31, 2019	December 31, 2018
Cash and cash equivalents	$ 957,889	$ 1,119,135
Investments	11,995,153	10,102,091
Pledges receivable	-	5,000
Total financial assets available within one year	12,953,042	11,226,226
Less: amounts unavailable for general expenditures within one year due to:		
Pledges approved to be paid within one year	(557,000)	(417,000)
Less: amounts unavailable to management without Board approval:		
Board designated net assets	(11,902,429)	(10,509,097)
Total financial assets available to management for general expenditure within one year	$ 493,613	$ 300,129

12. NEW ACCOUNTING STANDARDS UPDATE

FASB issued ASU No. 2016-02, Leases (Topic 842) in February 2016, which will supersede the current lease recording requirements in Topic 842. The ASU looks to increase transparency and comparability by conforming US GAAP with International Accounting Standards as it relates to leases. The new standard will require, among other things, that all leases, including operating leases, be included on the balance sheet as a "right of use" asset with an offsetting liability for the payments remaining on the lease. The new guidance will be effective for the Organization's year ending December 31, 2021, with early application permitted.

The Organization is currently evaluating the impact this standard will have on its financial statements.

13. SUBSEQUENT EVENTS

The Organization has evaluated subsequent events through July 23, 2020, the date that the financial statements were available to be issued.

As a result of the impact of COVID-19 (novel coronavirus), the Foundation is exposed to factors that will likely have negative impacts on its activities and financial position. Management cannot currently determine the ultimate impact this will have on the Foundation’s operations.